Multiple Sclerosis, Relapsing-Remitting

Neurology
34
Pipeline Programs
17
Companies
50
Clinical Trials
1 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
7
0
13
12
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
9100%
+ 27 programs with unclassified modality

On Market (7)

Approved therapies currently available

Sanofi
CAMPATHApproved
alemtuzumab
Sanofi
CD52-directed Cytolytic Antibody [EPC]intravenous2001
U
DIMETHYL FUMARATEApproved
dimethyl fumarate
Unknown Company
oral2020
Sanofi
LEMTRADAApproved
alemtuzumab
Sanofi
CD52-directed Cytolytic Antibody [EPC]injection2001
Roche
OCREVUSApproved
ocrelizumab
Roche
CD20-directed Cytolytic Antibody [EPC]injection2017
Roche
OCREVUS ZUNOVOApproved
ocrelizumab and hyaluronidase
Roche
Endoglycosidase [EPC]injection2024
Biogen
TECFIDERAApproved
dimethyl fumarate
Biogen
oral2013
Biogen
TYSABRIApproved
natalizumab
Biogen
Integrin Receptor Antagonist [EPC]single-use2004

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
13 programs
1
7
1
NatalizumabPhase 4Monoclonal Antibody1 trial
Dimethyl FumaratePhase 31 trial
NatalizumabPhase 3Monoclonal Antibody1 trial
NatalizumabPhase 3Monoclonal Antibody1 trial
NatalizumabPhase 3Monoclonal Antibody1 trial
+8 more programs
Active Trials
NCT04221191Completed353Est. Sep 2022
NCT04580381Completed500Est. Oct 2021
NCT03347370Completed626Est. Jul 2019
+10 more trials
Bayer
BayerLEVERKUSEN, Germany
4 programs
1
1
1
Interferon beta-1b, FRP within 15 days after randomizationPhase 41 trial
alemtuzumabPhase 3Monoclonal Antibody1 trial
Interferon beta 1bPhase 21 trial
Bayer/Cognitive Assessments With Multiple Sclerosis SubjectsN/A1 trial
Active Trials
NCT00888277Completed74Est. Jan 2010
NCT00235989Completed63Est. Jan 2008
NCT00930553Completed1,314Est. Feb 2016
+1 more trials
Sanofi
SanofiPARIS, France
2 programs
1
1
alemtuzumabPhase 3Monoclonal Antibody5 trials
Clinical assessmentN/A1 trial
Active Trials
NCT03768648Completed75Est. Feb 2023
NCT03983252Withdrawn0Est. May 2024
NCT05075499Unknown70Est. Sep 2022
+3 more trials
M&
Merck & Co.RAHWAY, NJ
2 programs
1
Cladribine 10 mg oral tabletPhase 41 trial
RebiSmart®2.0N/A1 trial
Active Trials
NCT02394782TerminatedEst. Mar 2016
NCT05902429Unknown10Est. Aug 2024
Genentech
GenentechCA - Oceanside
2 programs
2
OcrelizumabPhase 4Monoclonal Antibody1 trial
OcrelizumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT04261790Completed10Est. Nov 2024
NCT06495593Recruiting5Est. Dec 2025
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
1
OCREVUS ZUNOVO(Ocrelizumab)Phase 3Monoclonal Antibody1 trial
Active Trials
NCT03085810Terminated1,225Est. Apr 2023
Providence Therapeutics
2 programs
1
ACTHPhase 31 trial
Blood DrawN/A1 trial
Active Trials
NCT01909492CompletedEst. Oct 2023
NCT02315872CompletedEst. Dec 2018
Ipsen
IpsenChina - Tianjin
1 program
1
EGb 761®Phase 31 trial
Active Trials
NCT00276341Completed47Est. Dec 2005
Immunic Therapeutics
Immunic TherapeuticsGermany - Grafelfing
1 program
1
IMU-838 tabletsPhase 31 trial
Active Trials
NCT05201638Active Not RecruitingEst. Oct 2033
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]Phase 2
TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]Phase 21 trial
Active Trials
NCT04880577Withdrawn0Est. Feb 2025
Pfizer
PfizerNEW YORK, NY
1 program
1
CCI-779Phase 21 trial
Active Trials
NCT00228397Completed221Est. Nov 2005
Grifols
GrifolsNEW YORK, NY
1 program
1
Immune Globulin IV [Human], 10% Caprylate/Chromatography PurifiedPhase 21 trial
Active Trials
NCT00220779CompletedEst. Feb 2005
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
abataceptPhase 21 trial
Active Trials
NCT01116427CompletedEst. Feb 2015
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
1
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem CellsPhase 1/21 trial
Active Trials
NCT02418325TerminatedEst. Feb 2017
Takeda
TakedaTOKYO, Japan
1 program
1
ACTOSPhase 12 trials
Active Trials
NCT04943991Active Not Recruiting200Est. Oct 2024
NCT00242177Completed30Est. Oct 2005
Bristol Myers Squibb
1 program
A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyN/A1 trial
Active Trials
NCT05605782Active Not Recruiting9,000Est. Jul 2033

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenentechOcrelizumab
BiogenNatalizumab
Merck & Co.Cladribine 10 mg oral tablet
GenentechOcrelizumab
Sanofialemtuzumab
Sanofialemtuzumab
Sanofialemtuzumab
Sanofialemtuzumab
Sanofialemtuzumab
BayerInterferon beta-1b, FRP within 15 days after randomization
Immunic TherapeuticsIMU-838 tablets
BiogenDimethyl Fumarate
BiogenNatalizumab
Sanofialemtuzumab
RocheOcrelizumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 17,977 patients across 50 trials

NCT06495593GenentechOcrelizumab

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Start: Feb 2025Est. completion: Dec 20255 patients
Phase 4Recruiting
NCT05532163BiogenNatalizumab

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Start: Jan 2023Est. completion: Oct 20231 patients
Phase 4Terminated
NCT05902429Merck & Co.Cladribine 10 mg oral tablet

Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

Start: Apr 2021Est. completion: Aug 202410 patients
Phase 4Unknown
NCT04261790GenentechOcrelizumab

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Start: Aug 2020Est. completion: Nov 202410 patients
Phase 4Completed
NCT03135249Sanofialemtuzumab

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

Start: May 2018Est. completion: Nov 20209 patients
Phase 4Completed
NCT02419378Sanofialemtuzumab

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

Start: Jun 2015Est. completion: Nov 202015 patients
Phase 4Completed
NCT02255656Sanofialemtuzumab

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Start: Jan 2015Est. completion: Jul 20201,062 patients
Phase 4Completed
NCT02205489Sanofialemtuzumab

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Start: Oct 2014Est. completion: Apr 201658 patients
Phase 4Completed
NCT01757574Sanofialemtuzumab

Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

Start: Nov 2012Est. completion: Aug 20160
Phase 4Withdrawn
NCT00780455BayerInterferon beta-1b, FRP within 15 days after randomization

Rehabilitation Study in MS Patients

Start: Oct 2008Est. completion: Sep 20094 patients
Phase 4Terminated
NCT05201638Immunic TherapeuticsIMU-838 tablets

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Start: Jan 2022Est. completion: Oct 2033
Phase 3Active Not Recruiting
NCT03870763BiogenDimethyl Fumarate

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Start: Mar 2019Est. completion: Jul 202211 patients
Phase 3Terminated
NCT03689972BiogenNatalizumab

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Start: Nov 2018Est. completion: Jul 2023585 patients
Phase 3Completed
NCT03368664Sanofialemtuzumab

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Start: Oct 2017Est. completion: Sep 202516 patients
Phase 3Terminated
NCT03085810RocheOcrelizumab

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Start: Mar 2017Est. completion: Apr 20231,225 patients
Phase 3Terminated
NCT02555215Biogendimethyl fumarate

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Start: Feb 2016Est. completion: Sep 201820 patients
Phase 3Completed
NCT02525874Biogendimethyl fumarate

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Start: Aug 2015Est. completion: Apr 2018218 patients
Phase 3Completed
NCT02315872Providence TherapeuticsACTH

ACTH for Fatigue in Multiple Sclerosis Patients

Start: May 2015Est. completion: Dec 2018
Phase 3Completed
NCT02579681Biogendimethyl fumarate

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

Start: Apr 2014Est. completion: Dec 2016221 patients
Phase 3Completed
NCT01333358Sanofialemtuzumab

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Start: May 2011Est. completion: Mar 201430 patients
Phase 3Unknown
NCT01307332Sanofialemtuzumab

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

Start: Mar 2011Est. completion: Sep 201827 patients
Phase 3Completed
NCT00930553Bayeralemtuzumab

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Start: Aug 2009Est. completion: Feb 20161,314 patients
Phase 3Completed
NCT00276341IpsenEGb 761®

Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

Start: Aug 2003Est. completion: Dec 200547 patients
Phase 3Completed
NCT00030966BiogenNatalizumab

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Start: Jan 2002Est. completion: Dec 20051,200 patients
Phase 3Completed
NCT00027300BiogenNatalizumab

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Start: Nov 2001Est. completion: Jan 2005900 patients
Phase 3Completed
NCT00046683Sanofialemtuzumab

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

Start: Jul 2001Est. completion: Jun 2006284 patients
Phase 3Completed
NCT04880577Gilead SciencesTENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Start: Sep 2022Est. completion: Feb 20250
Phase 2Withdrawn
NCT02410200Biogendimethyl fumarate

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Start: Sep 2015Est. completion: Sep 201622 patients
Phase 2Completed
NCT01116427Allergy Therapeuticsabatacept

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

Start: Sep 2010Est. completion: Feb 2015
Phase 2Completed
NCT01186640Sanofialemtuzumab

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Start: Jun 2010Est. completion: May 201416 patients
Phase 2Completed
NCT00771602Sanofialemtuzumab

Alemtuzumab + Rituximab Consolidation in CLL

Start: Aug 2008Est. completion: Dec 20101 patients
Phase 2Terminated
NCT00228397PfizerCCI-779

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Start: Nov 2003Est. completion: Nov 2005221 patients
Phase 2Completed
NCT00235989BayerInterferon beta 1b

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Start: Jun 2003Est. completion: Jan 200863 patients
Phase 2Completed
NCT00220779GrifolsImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

Start: Dec 2002Est. completion: Feb 2005
Phase 2Completed
NCT00057967Sanofialemtuzumab

Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

Start: Jul 2000Est. completion: Jul 201037 patients
Phase 2Completed
NCT03983252Sanofialemtuzumab

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Start: Dec 2021Est. completion: May 20240
Phase 1/2Withdrawn
NCT02418325Genesis TherapeuticsAllogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start: Feb 2015Est. completion: Feb 2017
Phase 1/2Terminated
NCT00453427Sanofialemtuzumab

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

Start: Sep 2006Est. completion: May 201520 patients
Phase 1/2Completed
NCT00077961Sanofialemtuzumab

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Start: Dec 200349 patients
Phase 1/2Terminated
NCT00051701Sanofialemtuzumab

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Start: Dec 2002Est. completion: Aug 200561 patients
Phase 1/2Terminated
NCT03132584Sanofialemtuzumab

Cyclophosphamide and Alemtuzumab In Lymphoma

Start: Jul 2017Est. completion: Jan 20183 patients
Phase 1Terminated
NCT02583594Sanofialemtuzumab

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Start: Dec 2015Est. completion: Mar 202124 patients
Phase 1Completed
NCT00923182Sanofialemtuzumab

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Start: Feb 2010Est. completion: Aug 20116 patients
Phase 1Completed
NCT00330252Sanofialemtuzumab

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Start: May 2006Est. completion: Jan 201429 patients
Phase 1Completed
NCT00242177TakedaACTOS

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

Start: Oct 2003Est. completion: Oct 200530 patients
Phase 1Completed
NCT05605782Bristol Myers SquibbA Post-Authorization, Long-term Study of Ozanimod Real-world Safety

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Start: Sep 2021Est. completion: Jul 20339,000 patients
N/AActive Not Recruiting
NCT04943991TakedaACTOS

Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score

Start: Jul 2021Est. completion: Oct 2024200 patients
N/AActive Not Recruiting
NCT05075499Sanofialemtuzumab

Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Start: Mar 2021Est. completion: Sep 202270 patients
N/AUnknown
NCT04580381BiogenNatalizumab Injection [Tysabri]

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Start: Sep 2020Est. completion: Oct 2021500 patients
N/ACompleted
NCT04221191BiogenDimethyl Fumarate

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

Start: Aug 2019Est. completion: Sep 2022353 patients
N/ACompleted

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
4h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
4h ago

Director of Medical Affairs

CoMind
Miami, FL
4h ago

Director of Finance

CoMind
London, UK
4h ago

Electronics Engineering Manager

CoMind
London, UK
4h ago

Director of Information Technology

Zavation Medical Products
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

13 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 17,977 patients
17 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)